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Aspirin is an effective drug that, through inhibition of
platelet aggregation, has been shown to lower morbidity and
mortality in almost every aspect of coronary artery disease,
including primary prevention, secondary prevention after
acute myocardial infarction, unstable angina pectoris and
after coronary artery bypass graft surgery (1). It is inexpen-
sive and easy to use. Angiotensin-converting enzyme
(ACE) inhibitors are also effective drugs. In heart failure,
through a number of actions, including improved hemody-
namics centered on systemic arterial vasodilation, enhanced
renal perfusion and function, rectification of electrolyte
disturbances, arrhythmia suppression, as well as a favorable
influence on hypertrophy and cell proliferation, ACE in-
hibitors have been shown to ameliorate symptoms and lower
morbidity and mortality (2–6). Because coronary artery
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disease is the most common cause of heart failure, obviously,
there is considerable potential for combined treatment with
aspirin and an ACE inhibitor, with the intention of providing
the benefits of both drugs. Can we double the benefit? There
is abundant data from short-term experimental and clinical
investigations questioning the expedience of this practice, and
on the basis of results of major, controlled, long-term, morbid-
event studies of ACE inhibitors, the yield of the combination
appears to be a consistent lessening of the risk reduction of
cardiovascular events by about one-half.
The interaction is primarily between aspirin and the com-
pensatory hemodynamic mechanisms of heart failure and not
necessarily between aspirin and a given ACE inhibitor. How-
ever, because ACE inhibitors share and enhance the effects of
these desirable compensatory mechanisms, they are particularly
susceptible to the interaction and subsequently incur a loss of
benefits (7). The more severe the heart failure, the more
appreciable the interaction, and this thread goes back as far as
1980, before the era of ACE inhibitors, at which time both the
Aspirin in Myocardial Infarction Study (AMIS) and Persan-
tine Aspirin ReInfarction Study (PARIS) studies showed that
aspirin may be helpful in patients with well-preserved ventric-
ular function, but harmful in those with considerable ventric-
ular damage (8,9).
The pharmacodynamic actions of aspirin and ACE in-
hibitors are mutually counteractive. Consequently, it is not
surprising that we cannot obtain meaningful potentiation by
stimulating with one drug the same system we inhibit with
another. Angiotensin-converting enzyme inhibition pro-
motes prostaglandin synthesis. In addition to a reduction in
vasoconstrictive factors incurred through blockade of angio-
tensin II generation, ACE inhibitors also antagonize the
action of structurally identical kininase II, thereby impeding
the degradation of bradykinin, a potent vasodilator in its
own right, which also enlists further vasodilatory support by
enhancing production of prostaglandins. Aspirin, in con-
trast, inhibits prostaglandin synthesis, and its intended
action in coronary artery disease is achieved through block-
ade of the enzyme cyclooxygenase, which catalyzes the first
step in the biosynthesis of platelet thromboxane A2 and all
other prostaglandins from arachidonic acid.
Is the prostaglandin system really so important? In
normotensive, euvolemic, sodium-replete subjects, it may be
difficult to objectify any hemodynamic effects of prostaglan-
din synthesis inhibition. In hypertensive patients, however,
interactions with aspirin or other nonsteroidal anti-
inflammatory drugs have been known for many years; they
are easily detected and have been reported to attenuate the
blood pressure–lowering effects of nearly every antihyper-
tensive drug ever used clinically, such as beta-adrenergic
blocking agents, diuretics, direct-acting and alpha-blocking
vasodilators, as well as ACE inhibitors (10,11).
Analogously, in patients with left ventricular dysfunction
and no or only a mild degree of heart failure, the hemody-
namic effect of aspirin may be discrete and elude detection
on an individual basis. In patients with severe heart failure,
this is not the case. As the severity of the disease increases,
there is escalation of neurohumoral activity with increases in
vasoconstrictive angiotensin II, norepinephrine and vaso-
pressin, with a concomitant increase in vasodilator prosta-
glandin synthesis to a degree sufficient to restrain the pressor
action and maintain a balance of forces, albeit deranged
(12). Treatment with ACE inhibitors fortifies the restraint
of the prostaglandin system, the activity of which is also
stimulated by the use of diuretics. Under these circum-
stances, the relevance and magnitude of the restraining
forces can be best appreciated by turning them off. Instead
of the significant increase in cardiac output and significant
decreases in systemic vascular resistance and left ventricular
filling pressure when enalapril was given without aspirin,
when given with or on the day after a 350-mg dose of
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aspirin in a placebo-controlled study, enalapril did not elicit
significant changes in any hemodynamic variable (7). In
fact, when enalapril was given with or on the day after
aspirin, instead of a decrease in systemic vascular resistance,
which simply failed to materialize, as compared with pla-
cebo, there was an actual increase that persisted throughout
the day and at the baseline measurements on the following
day. When a similar protocol was used in patients with
comparably severe heart failure, these findings were con-
firmed by other investigators (13).
In heart failure, aspirin can not only offset the direct
hemodynamic benefits of ACE inhibition, but also encum-
ber optimal treatment through adverse effects on renal
function, which can surreptiously worsen the condition and
necessitate initiation of or increased use of diuretics. The
fact that aspirin and other nonsteroidal anti-inflammatory
drugs can cause depression of the glomerular filtration rate
not only in patients with compromised renal perfusion due
to heart failure or other causes, but also in normal subjects,
was documented decades ago (14,15). Here, too, the more
the prostaglandin system is activated to preserve renal
function, the more likely is a clinically manifest interaction.
The natriuretic effects of the diuretics used as a cornerstone
of most heart failure regimens are also attenuated by
interactions with aspirin and similar drugs (16,17). In
addition, the prostaglandins stimulated in response to ele-
vated levels of norepinephrine, angiotensin II and vasopres-
sin (i.e., heart failure) also function as a negative feedback
loop to restrain the action of vasopressin on hydroosmotic
water flow in the distal tubule and collecting ducts, and
experimental studies have repeatedly demonstrated en-
hanced vasopressin action after prostaglandin synthesis in-
hibition (18,19). In patients with severe heart failure,
despite diuretic treatment and ACE inhibition, which may
lower prevailing vasopressin levels, loss of the inhibitory
action of prostaglandins after a single dose of aspirin
imposed a further burden on circulatory homeostasis by
increasing total body water, with significant decreases in the
serum sodium concentration and plasma osmolality (20).
Not only does this dictate the need for higher diuretic
dosages, but also, in some patients, the changes in fluid
volume and composition were of sufficient magnitude to
result in hyponatremia, and this alone may be associated
with a less favorable prognosis (21).
Even though the prostaglandin-dependent hemodynamic
and renal effects of ACE inhibitors may be counteracted by
aspirin, ACE inhibition, per se, is still achieved when
aspirin is given concomitantly. Plasma active renin concen-
trations are increased, and there is a reduction in plasma
norepinephrine associated with slowing of the heart rate and
tendencial decreases in mean right atrial and pulmonary
artery pressures, indicating maintenance of prostaglandin-
independent effects (7). Effects on myocardial hypertrophy
and cell proliferation may be unaltered, but the clinical
relevance remains to be established. Arrhythmia suppres-
sion, which is more likely related to norepinephrine con-
centrations, may persist, and this could account for the
findings in the second Veterans Administration Vasodilator
Heart Failure Trial (V-HeFT II) comparing enalapril with
the combination of hydralazine and isosorbide dinitrate (2).
About one-half of the patients had coronary artery disease,
and it is reasonable to assume that the majority was taking
aspirin, although the number was not specified. In patients
without coronary artery disease, there was a trend toward a
preferential beneficial effect on mortality, and those taking
enalapril fared better than those taking hydralazine plus
isosorbide dinitrate. Overall, there was no difference in
mortality from pump failure between the two drug regi-
mens, and the significantly better outcome in the enalapril
group was exclusively due to a reduction in sudden death.
Here, the question arises whether it could be possible that,
in patients with coronary artery disease, vasodilation with
either an ACE inhibitor or hydralazine plus isosorbide
dinitrate was equally affected by aspirin, leading to no
change in heart failure deaths. Other major studies have also
demonstrated some benefits of treatment with an ACE
inhibitor when aspirin was given concomitantly, however,
the benefits were conspicuously and consistently less in
patients reported to be taking aspirin, and in those studies in
which the number of patients taking aspirin was not
reported, in those with coronary artery disease who were
more likely to be taking aspirin (Table 1). Even in patients
with no overt manifestations of heart failure in the Studies
Of Left Ventricular Dysfunction (SOLVD) Prevention trial,
possibly by virtue of the large number of patients, there was a
significantly lesser reduction in mortality by enalapril in pa-
tients taking aspirin (22), and, similarly, significantly less
favorable outcome of treatment with enalapril was reported in
patients also taking aspirin from the combined analysis of the
SOLVD Prevention and Treatment trials. In two other stud-
ies—the Survival And Ventricular Enlargement (SAVE) study
using captopril (5) and the Acute Infarction Ramipril Efficacy
(AIRE) study (6)—both of which enrolled only about one-half
of the number of patients as in the SOLVD Prevention trial,
the trend toward a more favorable outcome without aspirin was
unmistakable, and this was explicitly pointed out by the
authors of the latter study.
The second COoperative North Scandinavian ENalapril
SUrvival Study (CONSENSUS II) (23), one of the largest
of the studies, showed a trend toward less favorable outcome
in patients receiving enalapril as compared with placebo. In
an analysis performed subsequently, specifically to address
the question of an interaction between aspirin and ACE
inhibitors, a significant excess in mortality was observed
when enalapril was randomized to patients using aspirin
(24). In all of these studies, it was apparent that ACE
inhibitors work better when given without aspirin. Depend-
ing on the degree of heart failure and neurohumoral
activation, the magnitude of the interaction may range from
subtle to overt. Moreover, it appears that the clinical
problem cannot be circumvented with an aspirin-based
compromise using low doses. Our hospital records docu-
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Table 1. Risk Reduction in Major Heart Failure Studies of Angiotensin-Converting Enzyme Inhibitors
Study (ref.) Drug (Dose) CAD (%) Aspirin* (%) DRisk† (%) Comment
AIRE (6) n 5 2,006
AC: AMI, clinical
evidence of heart
failure
Ramipril
(10 mg in 77%)
vs. placebo
All Ramipril (77%)
Placebo (78%)
Aspirin (215%)
No aspirin (227%)
Authors: “even
greater benefit
in those not
receiving
aspirin.”
CONSENSUS II (23)
n 5 6,090
AC: AMI, heart failure
in 19%
Enalapril
(20 mg in 82%)
vs. placebo
All Enalapril (77%)
Placebo (78%)
Enalapril (8%)
(vs. placebo)
Significant excess
in mortality in
patients with
enalapril and
aspirin.
SAVE (5) n 5 2,231
AC: AMI, EF #40%,
asymptomatic
Captopril
(150 mg in 79%)
vs. placebo
All Captopril (59%)
Placebo (59%)
Aspirin (220%)
No aspirin (229%)
SOLVD (4) Prevention
n 5 4,228
AC: EF #35%,
asymptomatic
Enalapril (17 mg)
vs. placebo
Enalapril (83%)
Placebo (83%)
Enalapril (56%)
Placebo (53%)
Not reported Significantly lesser
effect on
mortality in
patients taking
aspirin.
SOLVD (3) Treatment
n 5 2,569
AC: EF #35%,
NYHA class II/III
Enalapril (16 mg)
vs. placebo
Enalapril (70%)
Placebo (72%)
Enalapril (33%)
Placebo (34%)
CAD (212%)
No CAD (227%)
Significantly less
favorable
outcome in
patients with
aspirin
(combined
analysis with
SOLVD
Prevention).
V-HeFT II (2) n 5 804
AC: EF #45%, peak
oxygen consumption
,25 ml/kg per min
Enalapril (15 mg)
vs. hydralazine
(199 mg) 1
ISDN (100 mg)
Enalapril (54%)
Hydralazine 1
ISDN (51%)
Not reported CAD (213%)
No CAD (226%)
Mortality reduction
only with
enalapril and
only due to a
reduction in
sudden deaths
but not heart
failure deaths.
Latini et al. (25)
n 5 96,712
AC: AMI
(meta-analysis: CCS-1,
CONSENSUS II,
GISSI-3, ISIS-4)
Various ACE
inhibitors
vs. control
All ACE inhibitors
(91%)
Control (90%)
Heart failure
Aspirin (23%)
No aspirin (29%)
7-Day mortality
Aspirin (27%)
No aspirin (215%)
30-Day mortality
Aspirin (26%)
No aspirin (210%)
*This includes patients reported to be taking aspirin, or, if the number of those taking aspirin was not reported, patients with coronary artery disease who were more likely to
be taking aspirin. In patients taking aspirin, the risk reduction is consistently about one-half of that of patients not taking aspirin. †Reported change (D) in precent risk of a
cardiovascular event.
Data in parentheses for coronary artery disease (CAD), aspirin and D risk are presented as percentage of patients.
AC 5 admission criteria; ACE 5 angiotensin-converting enzyme; AIRE 5 Acute Infarction Ramipril Efficacy; AMI 5 acute myocardial infarction; CCS-1 5 Chinese
Cardiac Study; CONSENSUS II 5 second COoperative North Scandinavian ENalapril SUrvival Study; EF 5 ejection fraction; GISSI-3 5 Gruppo Italiano per lo studio della
nell’ Infarto myocardico; ISDN 5 isosorbide dinitrate; ISIS-4 5 International Study of Infarct Survival; NYHA 5 New York Heart Association; SAVE 5 Survival And
Ventricular Enlargement; SOLVD 5 Studies Of Left Ventricular Dysfunction; V-HeFT II 5 Veterans Administration Vasodilator Heart Failure Trial.
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ment that, on repeated occasions, in some patients with
otherwise terminal, catecholamine-dependent heart failure,
marked hemodynamic improvement, stabilization and
abatement of hyponatremia with reduced diuretic dosages
resulted from discontinuation of a daily, 100-mg dose of
aspirin with no additional therapeutic manipulations.
In this issue of the Journal, Latini et al. (25) report the
meta-analyzed data from a vast number of patients in four of
the largest multicenter studies ever undertaken (Chinese
Cardiac Study [CCS-1], CONSENSUS II, Gruppo Ital-
iano per lo Studio della Sopravvivenza nell’Infarto Mio-
cardico 3 [GISSI-3] and International Study of Infarct
Survival 4 [ISIS-4]) (24). There were no significant differ-
ences in the risk reductions after acute myocardial infarction
with an ACE inhibitor in the two groups of patients: those
concomitantly treated with aspirin and those who did not
receive aspirin. Consequently, the investigators surmise that
guidelines suggesting a possible negative interaction be-
tween aspirin and ACE inhibitors should be reconsidered.
So let’s reconsider.
The most obvious limitation of the interpretation of their
results is that the two groups of patients are substantially
disparate; the 30-day mortality rate in those receiving
aspirin was 7%, and those who did not receive aspirin had a
30-day mortality rate of 14%. The difference was significant,
but the reasons for giving or withholding aspirin were not
reported. The latter group of patients was older and sicker.
In addition, at about one-tenth the size, the no-aspirin
group is decisively at a statistical disadvantage. What we can
derive from their analysis is that the combination of an
ACE inhibitor and aspirin does, in fact, reduce mortality
(albeit, from 6.7% to 6.3%—not very impressive). However,
nearly identical figures have been reported in the other
studies, and even ISIS-4, which supplied ;60% of the
patients, characterized this reduction as “only moderate.”
None of the four studies, in which almost 90% of the
patients were taking aspirin, was able to show a significant
reduction in heart failure with the various ACE inhibitors,
and in three of the four studies, the incidence of cardiogenic
shock was increased, in one significantly. The combined
analysis showed that the trend toward a proportional reduc-
tion in heart failure in patients receiving aspirin (3.3%),
again, was less than one-half of that in those not receiving
aspirin (8.8%). This leaves open a distinct possibility that
the difference could be significant if there had been 90,000
patients in the non-aspirin group. Differences in the reduc-
tion of seven-day mortality (15% vs. 7%) and 30-day
mortality (10% vs. 6%) in control subjects in the no-aspirin
and aspirin groups, respectively, are discarded as nonsignif-
icant. On the basis of the available data, however, the study
by Latini et al. had only 13% power to detect whether any
of these differences are significant. Interestingly, in the
studies included in their analysis, there were also no signif-
icant reductions in postinfarction angina, the need for
interventions, reinfarction or ventricular fibrillation. If you
are still wondering exactly what the ACE inhibitor did, the
question is justified. Apparently, the only significant result
was an excess of stroke in the aspirin group as compared
with the no-aspirin group.
Latini et al. (25) have not made their case for zero
interaction. Although there may be some short-term benefit
of giving enalapril and aspirin to patients with acute
myocardial infarction, for those who have done investiga-
tions to determine whether this benefit is really the best we
can do for our patients, the argument is not very persuasive
and, in any case, cannot be extrapolated to long-term
treatment. Directly or indirectly, studies such as AIRE and
ISIS-4 have already addressed the issue, and not one, except
perhaps for CONSENSUS II, has shown that ACE inhib-
itors are of no benefit when given together with aspirin.
Nevertheless, numerous studies have reported that without
aspirin, the benefits of ACE inhibitors are more favorable
than with aspirin. Basically, Latini et al. have done more to
corroborate than refute this. Table 1 shows that the extent
of attrition of the risk reduction—invariably about one-
half—is the same as that seen in other major studies, either
as a trend or a significant difference. Without a comparable
control group (an approximate number of “healthy” patients
with infarction with a 30-day mortality rate of ;7% who
did not receive aspirin, or a similar number of “sick” patients
with infarction with a 30-day mortality rate of 14% who did
receive aspirin), a valid comparison cannot be made; again,
if an appropriate control group had been available, it is
possible that in this study, too, without aspirin, the risk
reduction for heart failure and mortality may have been
statistically greater.
In conclusion, if guidelines exist, there is no convincing
reason to abandon them. To whatever extent the improve-
ment in symptoms and survival rendered by treatment with
ACE inhibitors is attributable to their effects on the
circulation and kidneys, this benefit can be rescinded by
concomitant administration of aspirin. Although some use-
ful prostaglandin-independent actions may persist, shutting
down the entire prostaglandin system at the level of cyclo-
oxygenase and trading off about one-half of the potential
risk reduction, with forfeit of salutary hemodynamic and
renal effects, is a high price to pay just to stop production of
thromboxane A2.
Accordingly, for patients requiring long-term treatment
for heart failure, the physician is still well advised, if
possible, to avoid aspirin and to respect the integrity of
prostaglandin metabolism—the more severe the heart fail-
ure, the more compelling. There are other ways to inhibit
platelet aggregation, and some are equally effective or even
better than aspirin. Orally active platelet glycoprotein IIb/
IIIa receptor antagonists, which promise to be substantially
more efficient than aspirin, have been developed and are
now in clinical testing. Ticlopidine and clopidogrel, al-
though more expensive than aspirin, can be used as an
alternative. As another option, because patients with more
severe heart failure are likely to be those with very low
ejection fractions, they are good candidates for oral antico-
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agulation, even though this treatment requires additional
monitoring.
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